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Abstract 
Endothelial cells (EC) are involved in regulating several aspects of lipid metabolism, with recent research 
revealing the clinicopathological significance of interactions between EC and lipids.  Induced pluripotent 
stem cells (iPSC) have various possible medical uses, so understanding the metabolism of these cells is 
important.  In this study, endothelial phenotype cells generated from human iPSC formed cell networks in 
co-culture with fibroblasts.  Changes of plasmalogen lipids and sphingomyelins in endothelial phenotype 
cells generated from human iPSC were investigated by reverse-phase ultra-high-pressure liquid 
chromatography mass spectrometry (UHPLC-MS/MS) analysis.  The levels of plasmalogen 
phosphatidylethanolamines (38:5) and (38:4) increased during differentiation of EC, while sphingomyelin 
levels decreased transiently.  These changes of plasmalogen lipids and sphingomyelins may have 
physiological significance for EC and could be used as markers of differentiation. 
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Introduction 
   Endothelial cells (EC) are multifunctional cells with a role in regulating coagulation and fibrinolysis, 
vascular tone, angiogenesis, and inflammatory reactions, and EC dysfunction is involved in the 
pathophysiology of various diseases1,2.  With regard to respiratory diseases, vasodilation contributes to 
limitation of airflow in asthma3-5, and EC dysfunction is related to smoking–induced chronic obstructive 
pulmonary disease (COPD)6.  In patients with cardiovascular disease, EC injury or dysfunction is the first 
step toward the development of atherosclerosis7, 8.   
Stem cells are expected to have medical applications in cell therapy for the above-mentioned diseases.  
EC derived from mouse or human induced pluripotent stem cells (iPSC) were reported in 2008 and 2009 by 
the same group9,10, and it has been shown that cells positive for Flk1 (also known as KDR/vascular 
endothelial growth factor receptor 2, VEGFR2) and VE-cadherin differentiate into EC11.  Engineering of 
the pulmonary vasculature has been performed in decellularized rat and human lungs by using EC and 
perivascular cells derived from iPSC12.  Furthermore, patient-specific EC derived from iPSC have 
demonstrated a protective effect against pulmonary hypertension in familial pulmonary arterial hypertension 
with bone morphogenetic protein receptor type 2 (BMPR2) mutation13.  Moreover, EC derived from iPSC 
demonstrate endothelial functionality in vitro and have been shown to promote neovascularization and 
enhance restoration of blood flow in animal models of myocardial infarction and peripheral arterial disease14.  
Thus, EC derived from iPSC have the potential for various medical applications15, 16, but elucidation of the 
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biological features of these cells is required before clinical use can be attempted.    
Glycerophospholipids are components of lipid bilayer membranes that are classified into three groups 
based on sn-1 linkage. Diacyl glycerophospholipids have a diester linkage at the sn-1 and sn-2 positions, 
plasmanyl glycerophospholipids have an ether linkage at the sn-1 position, and plasmalogens (also known as 
plasmenyl glycerophospholipids) contain a vinyl ether linkage at the sn-1 position. Typical plasmalogens 
have C16:0, C18:0, or C18:1 at the sn-1 and a polyunsaturated fatty acid at the sn-2 position17, 18. The most 
common plasmalogens in total phospholipids are plasmalogen phosphatidylethanolamines (pPE: 5%-22%) 
and plasmalogen phosphatidylcholines (pPC: 0.8%-22%), whereas serine or inositol plasmalogens are rare17.  
However, the levels of these plasmalogens vary among cells or tissues17.  The antioxidant effect of 
endogenous plasmalogens has been examined in detail, and plasmalogens have been shown to protect EC 
from hypoxic stress and reactive oxygen species (ROS)19.  Reduced levels of plasmalogens have been 
reported in ageing, dyslipidemia, Alzheimer's disease, smoking, and coronary artery disease20-24.   
Sphingomyelins (SM) are basic components of cell membranes and a major source of ceramides, with 
production being regulated by SM synthases (SMS) and sphingomyelinases (SMases)25.  High plasma SM 
levels were reported to predict more rapid annual progression of pulmonary emphysema26.  Inhibition of 
SMS in EC was reported to attenuate lipopolysaccaride (LPS)-induced lung injury in animals through 
enhancement of the EC barrier by reducing loss of SM from lipid rafts in the cell membrane27.  Elevated 
plasma SM levels are a prognostic marker in acute coronary syndrome28, and overexpression of SMS is 
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suggested to be related to EC dysfunction, a decrease of CD34/KDR-positive endothelial progenitor cells, 
and development of atherosclerosis in ApoE knock-out mice29.  Thus, plasmalogens and SM play an 
important role in EC function and their plasma levels reflect various disease states.  Therefore, elucidating 
the behavior of plasmalogens and SM in iPSC-derived EC during differentiation could be helpful for 
evaluating the potential of medical applications of EC generated from iPSC.         
In the present study, endothelial phenotype cells were generated from human iPSC, and the levels of 
pPE and pPC (major components of plasmalogen lipids) and SM were examined in iPSC-derived EC by 
liquid chromatography-mass spectrometry (LC-MS).  Levels of these lipids were evaluated during 
differentiation of iPSC to endothelial phenotype cells and were compared with the levels in established cell 
lines of EC and fibroblasts.       
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Results 
Induction and purification of endothelial cells  
   Induction of EC from iPSC was performed as shown in Figure 1.  Pluripotency of feeder-free iPSC was 
confirmed by SSEA-4 immunofluorescence staining and the alkaline phosphatase assay (supplementary 
Figure S1).  On day 5 of culture, cells were sorted by a FACSAria® FACS with KDR and VE-cadherin 
fluorescent labeling.  Mesodermal cells (MC) were defined as KDR+/VE-cadherin- cells, while EC were 
KDR+/VE-cadherin+ cells.  The mean percentage of MC differentiated from iPSC was 18.0 ± 1.2 % on day 
4, 11.0 ± 5.5 % on day 5, and 20.6 ± 2.0 % on day 6.  In addition, the mean percentage of EC sorted from 
the cultures (iEC) was 11.9 ± 2.4 % on day 4, 10.9 ± 2.6 % on day 5, and 7.4 ± 0.5 % on day 6 
(supplementary Figure S2a S2b).  The initial morphological changes as iPSC underwent differentiation into 
iEC were observed on day 3 or 4.  Typical iPSC are characterized by large nuclei and scanty cytoplasm, but 
these features were modified on days 3 to 4 (supplementary Figure S2c).      
 
Purification of endothelial cells derived from iPSC and functional assessment  
The iEC but not MC were subcultured at least twice (ECpa), immunostaining was done with anti-KDR, 
anti-VE-cadherin, anti-PECAM-1 and anti-vWF antibodies.  Most ECpa (nearly 100 %) were positive for 
KDR, VE-cadherin, PECAM-1 and vWF while iPSC were negative for these markers (Figure 2a).  The 
expression of vWF mRNA measured by quantitative PCR was significantly higher in iEC or ECpa compared 
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with iPSC.  Immunostaining also showed that iEC were positive for vWF antibody (supplementary Figure 
S3).  To assess the functional characteristics of ECpa, the tube formation assay was performed.  ECpa 
were round single cells shortly after seeding (Figure 2bi), but started to form networks after incubation for 2 
hours. Network formation was maximal around 4 to 12 hours (Figure 2bii), after which agglomeration of the 
networks occurred. To evaluate tube-forming capacity in co-culture, ECpa were co-cultured with human 
fetal lung fibroblast-1 (HFL-1) cells, followed by immunostaining with PECAM-1 (green) to detect ECpa 
and DAPI (blue) for nuclei.  Network formation by ECpa was confirmed by detection of 
PECAM-1-positive networks in the co-cultures (Figure 2ci).  At a higher magnification, fluorescent 
immunostaining showed that networks were formed sterically between HFL-1 cells (Figure 2cii). Without 
immunostaining, the ECpa networks were difficult to distinguish from HFL-1 cells (supplementary Figure 
S4).  ECpa purification efficiency was confirmed by VE-Cadherin / PECAM-1 double positive ratio.  
Nearly 90% of ECpa was VE-cadherin+ / PECAM-1+ positive (supplementary Figure S5). 
 
Results of LC-MS/MS 
   Lipids were collected from iPSC in feeder-free culture on day -2 before induction of differentiation.  
MC and iEC were sorted on day 5 (KDR+/VE-cadherin- cells were defined as MC and KDR+/VE-cadherin+ 
cells were defined as iEC).  The contents of pPE, pPC, and SM were measured in iPSC, MC, iEC, and 
ECpa.  Internal standards for pPE, pPC, and SM were phosphatidylethanolamine (PE) (34:0), 
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phosphatidylcholine (PC) (30:0), and SM (35:0), respectively.  These standards (1 μg) were added to 100 
μg of protein solution at the purification step.  In Figures 3 and 4, ratios to the internal standards are shown 
on the vertical axis.  Levels of pPE(38:5), pPE(38:4), pPE(40:6), pPE(40:5), and pPE(40:4) were 
significantly increased in MC, iEC, and ECpa compared with iPSC, and were especially high in ECpa.  The 
pPE (38:6) level was not significantly higher in MC and iEC than in iPSC, but increased markedly after 
passaging as shown in ECpa (Figure 3a).  Levels of pPC (36:4) to pPC (40:1) were not significantly 
different among iPSC, MC, and iEC, but were significantly higher in ECpa compared with the other cells 
(Figure 3b).  On the other hand, SM showed a transient decrease during differentiation of MC and iEC, and 
subsequently increased in ECpa (Figure 3c).   
Since pPE and pPC were significantly increased in ECpa, the levels of these lipids were compared 
between ECpa and HUVEC, which are regarded as mature EC.  Levels of pPE components were not 
significantly different between ECpa and HUVEC (Figure 4a), but levels of pPC components were 
significantly lower in HUVEC (Figure 4b).  SM showed a transient decrease during differentiation, so SM 
components were also compared between ECpa and HUVEC.  SM (36:1) and SM (36:0) were higher in 
ECpa than HUVEC, but other SM components were low, except for SM (38:0) (Figure 4c).  Since 
fibroblasts are usually derived from MC, the pPE, pPC, and SM levels were also measured in HFL-1 cells, 
which are fibroblasts.  It was found that the levels of pPE (38:5), pPE (38:4), pPE (40:6), pPE (40:5), and 
pPE (40:4) were significantly higher in ECpa than HFL-1 cells, but pPE(38:6) was not significantly different 
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(Figure 4d).  While pPC levels were significantly higher in ECpa than in HFL-1 cells, the differences were 
smaller than those observed for pPE (Figure 4e).  In addition, the levels of SM(36:1), SM(36:0), SM(38:1), 
SM(40:1), and SM(42:0) were significantly higher in ECpa than in HFL-1 cells, but SM(34:0) was lower in 
ECpa cells (Figure 4f).  Culture medium were needed to be preparing for each cell lines because of keeping 
their phenotype, such as pluripotency, EC or fibroblasts.  Since culture medium would affect the cellular 
phospholipid contents, levels of pPE, pPC and SM in culture medium were measured.  Most of pPE and 
pPC levels in medium were low of under detection levels, however SM (34:0) was confirmed high in F12K 
(supplementary Figure S6).       
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Discussion 
   In the present study, human EC (characterized as KDR+ PECAM-1+VE-cadherin+VWF+ cells) generated 
from human iPSC showed angiogenic potential and ECpa also formed cellular networks in co-culture with 
fibroblasts.  During differentiation from iPSC to EC, the pPE level increased significantly.  In addition, 
pPE levels were similar in ECpa and HUVEC, indicating that pPE is a potential marker for endothelial 
phenotype cells.   
Several methods of inducing EC from iPSC have been reported 30, 31.  Kohler et al. developed a 
simple and excellent method for generating functional murine EC from murine iPSC30, and we modified 
their method for use in the present study.  In order to increase the number of attached iPSC in feeder-free 
dishes, we used laminin-511-E8 (iMatrix511®) to coat the dishes instead of type IV collagen before seeding 
iPSC, while Matrigel® was used to reduce the number of cells becoming detached from the culture dishes at 
the first step of induction, which was addition of cytokines.  Laminin-511-E8 and Matrigel® contain several 
matrixes and collagens, and have been reported to provide support or increase the efficiency of iPSC 
adhesion and growth32.  Since we could not obtain enough EC for subculture by the original method30, we 
modified it for this study (supplementary Figure S7).  The reasons for the lower efficiency of inducing EC 
than previously reported are unknown, but technical matters or use of different cell lines might have had an 
influence.  Previous report30 used the pre-coated dish of unknown concentration of type IV collagen 
coating.  In present study, type IV collagen was tested at the similar concentration to Laminin-511-E8.  
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This also might have had an influence.  However, the cells derived from iPSC by our modified method 
were confirmed to have the characteristics of EC by immunofluorescence and functional assessment, as 
reported previously30 33.  After these EC were passaged (ECpa), the cells formed networks in co-culture 
with HFL-1 cells.  HFL-1 cells are known to be fibroblasts that undergo transformation to the contractile 
phenotype of myofibroblasts in response to certain stimuli34.  The existence of myofibroblasts in interstitial 
tissue has been reported in pulmonary fibrosis, and myofibroblasts contribute to the development of 
fibrosis35.  In order to generate EC from the iPSC of patients with diseases such as pulmonary fibrosis, this 
co-culture system could be used as a tool for analysis of the influence of various stimuli in a pulmonary 
fibrosis model.        
Plasmalogen phospholipids have been identified in murine embryonic stem cells (ESC), iPSC, and 
fibroblasts.  It was reported that the cellular content of pPE (34:1), pPE (34:2), and pPE (36:2) was higher 
in fibroblasts than in ESC or iPSC, while the level of pPE (34:2) was lower in fibroblasts than in ESC or 
iPSC.  In addition, the pPC (34:1) content was higher in fibroblasts than in ESC and iPSC, while the pPC 
(36:4) content was lower in fibroblasts than in ESC and iPSC36.  The present study showed that the levels 
of pPE (38:6), pPE (38:5), pPE (38:4), pPE (40:6), pPE (40:5), and pPE (40:4) all increased significantly 
during differentiation of iPSC to iEC and after passaging of iEC (ECpa).  Most of the pPCs, especially pPC 
(36:3), pPC (36:2), pPC (36:1), pPC (36:0), pPC (38:4), pPC (38:3), and pPC (38:2), showed similar 
changes to those of the pPEs.  These findings suggest that most plasmalogens might increase during 
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differentiation to mature cells such as fibroblasts and EC.  Since it is known that pPE is metabolized to 
pPC, the increase of pPC might be secondary to elevation of pPE37.  
We compared plasmalogen levels in ECpa with those in HUVEC (endothelial cells) and HFL-1 cells 
(fibroblasts).  Detection of pPE and pPC in HUVEC was reported previously38.  The pPE levels were not 
different between ECpa and HUVEC in present study.  When the levels of pPE (38:5) and pPE (38:4) were 
compared between ECpa and HFL-1 cells, both pPE (38:5) and pPE (38:4) were significantly higher in 
ECpa cells.  In short, these results investigations revealed that pPE (38:5) and pPE (38:4) levels showed a 
marked increase during culture of iEC to ECpa, with pPE (38:5) and pPE (38:4) levels also being increased 
in other mature EC and higher than in HFL-1 cells.  Taken together, these results suggest that pPE (38:5) 
and pPE (38:4) could be markers for EC phenotype acquisition.   
   Metabolic signatures and markers are important when considering medical applications of cells.  EC 
generated from iPSC are usually identified from cell surface markers (KDR+ PECAM-1+VE-cadherin+) and 
from the ability to promote angiogenesis in vitro or in vivo14, 30.  Previous studies have shed some light on 
the dynamic barrier properties (influenced by multiple vascular permeability factors) of EC generated from 
iPSC39, as well as transcriptional and metabolic changes during maturation of EC differentiated from iPSC40.  
Plasmalogens play an important role in the response of EC to disease, and supplementation of plasmalogens 
was reported to support retinal vascular development41.  Therefore, when considering the application of 
generated EC for cell therapy, it may be useful to evaluate the levels of plasmalogens such as pPE (38:5) and 
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pPE (38:4).  Plasmalogens contain a vinyl ether linkage at the sn-1 position and polyunsaturated fatty acids 
at sn-217.  The fatty acids at sn-1 or sn-2 could not be determined in present study.  However, it is known 
that the sn-1 position is commonly occupied by a C16:0 or C18:0 or C18:1 fatty acid and the sn-2 position is 
commonly occupied by arachidonic acid (AA 20:4) or docosahexaenoic acid (DHA C22:6)37.  Therefore, 
pPE (38:5) and pPE (38:4) are possibly composed of the combination of C18:0 or C18:1 and AA 20:4, 
respectively.  When pPC levels were compared between ECpa and HUVEC or HFL-1 cells, large 
differences like those of pPE were not observed, suggesting that there might be differences in the 
metabolism of pPE and pPC.  Taken together, pPE (38:5) and pPE (38:4) could be markers for EC.        
The pathophysiological importance of pPE and pPC has been reported.  Increased serum levels of pPE 
(38:5) and pPE (38:4) are associated with a higher risk of myocardial infarction42.  High-density 
lipoprotein cholesterol (HDL-C) contributes to plaque regression43, and the levels of pPE (38:6), pPE (40:6), 
and pPC (36:4) were significantly increased in HDL-C compared to low-density lipoprotein cholesterol 
(LDL-C) by statin therapy in patients with dyslipidemia44.  In addition, hypoxia caused a decrease of pPE 
in human pulmonary arterial endothelial cells (HPAEC), while supplementation of plasmalogens protected 
HPAEC from hypoxia19.  As described above, pPE (38:5) and pPE (38:4) may be composed of AA, so 
these lipids could be storage sites for inflammatory lipid mediators in EC37.  Because EC lining blood 
vessels are exposed to oxidative stress, an increase of plasmalogens might protect these cells against such 
stress.   
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SM levels declined transiently during differentiation of iPSC to MC and EC.  SM accounts for 
about 10% of total lipids in HUVEC38.  Sphingosine-1-phosphate (S1P) is a lipid mediator formed from 
SM that has an important role in embryonic angiogenesis45.  SM is a basic component of cell membranes, 
and is a major source of ceramides regulated by SMS and SMases, as described above25.  Inhibition of 
SMS was found to enhance the barrier function of EC via changes of the actin cytoskeleton that resulted in 
reduction of the loss of SM from lipid rafts in cell membranes27.  In the present study, changes of cell 
morphology were noted during differentiation, suggesting that dynamic changes of the actin cytoskeleton 
occur with differentiation.  The transient decrease of SM might have occurred because it is metabolized 
and consumed during differentiation.  A previous study showed that SM (34:2) was lower in murine iPSC 
than murine fibroblasts36, and the present study also demonstrated that the levels of most SM components 
were lower in iPSC than ECpa.  When the SM levels in ECpa were compared to those in HUVEC 
(endothelial cells) and HFL-1 cells (fibroblasts), most SM levels were lower in ECpa than HUVEC, except 
for SM (36:0) and SM (36:1), while the SM levels of ECpa varied in comparison to those of HFL-1 cells.  
From these findings, SM levels in cells vary among different cell types.  SM (34:0) was lower in ECpa than 
HFL-1.  HFL-1 was cultured by F12K® medium and F12K® contained much of SM (34:0) as shown 
supplementary data Fig S6.  SM(34:0) in F12K medium might have had a influence of SM(34:0) in HFL-1.  
In short, SM might be consumed during differentiation and possibly contributes to differentiation from iPSC 
to EC.   
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   In a clinical study, high plasma SM levels were markers for more rapid annual progression of pulmonary 
emphysema 26, and elevation of plasma SM was observed in patients with cystic fibrosis 46.  SM levels also 
increase in patient with acute coronary syndrome42.  These data suggest that SM could be a marker for 
tissue remodeling or acute EC injury, but further study of the changes of SM in EC is needed. 
   There were several limitations of present study. First, we only examined the levels of plasmalogens and 
SM. However, to reveal the entire lipid metabolic signature of EC, it would be necessary to also investigate 
other lipids, such as PC, PE, phosphatidylserines (PS), and lysophosphatidic acids (LPA).  Although there 
are no simple and established methods for induction of cells other than EC from iPSC, evaluating the 
changes of pPE levels during differentiation or in response to various stimuli when compared with other 
cells derived from iPSC or iPSC generated from different resources could help to determine the 
physiological significance of pPE in ECpa.  Furthermore, we employed co-culture of iPSC-derived EC and 
HFL-1 cells, but EC derived from iPSC are not necessarily the same as native EC.  When HUVEC were 
cultured until the 14th passage, oxidized LDL levels, tumor necrosis factor-alpha-induced apoptosis, and 
caspase-3 activity were all significantly enhanced by more than 3-fold compared with young cells in the 3rd 
passage47.  The metabolic signature of senescence in donor iPSC might affect generation of EC from 
iPSC48, 49.  Therefore, to evaluate the usefulness of the present co-culture system, it would be better to 
examine the metabolic signature of EC senescence by longer passaging.   
In conclusion, metabolism of plasmalogens (especially pPE) and SM showed various changes during 
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differentiation of iPSC to EC and subsequent culture of EC phenotype acquisition.  This is the first report 
about the changes of plasmalogens during differentiation of iPSC to EC.  pPE (38:5) and pPE (38:4) could 
be markers for mature EC, while a decrease of SM is a transient marker for MC and immature EC.  These 
lipids may be associated with differentiation of iPSC to EC, but further analysis is needed to elucidate their 
functional significance.  
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Materials and methods 
Cell culture  
   Human iPSC were purchased from RIKEN-BRC (409B2, obtained from a healthy 36-year-old woman), 
and the mouse embryonic fibroblasts cell line (SNL76/7) was purchased from the European Collection of 
Authenticated Cell Cultures (ECACC)50.  Human umbilical vein endothelial cells (HUVEC) and human 
fetal lung fibroblast-1 (HFL-1) cells were obtained from the American Type Culture Collection (ATCC).  
The following media were used for cell culture: Primate ES Cell medium® (ReproCell) with 4 ng/mL bFGF 
(ReproCell) for feeder iPS culture, StemFit® (ReproCell) for feeder-free iPSC culture, Dulbecco's modified 
Eagle’s medium® (DMEM, Nacalai Co. Ltd., Japan) with 7% fetal bovine serum and penicillin-streptomycin 
for SNL76/7 cells, VEGF Comp Kit® medium for HUVEC and EC derived from iPSC, and Ham's F-12K 
(Kaighn's)® medium (Thermo Fisher Scientific) with 10% fetal bovine serum albumin (BSA) and 
penicillin-streptomycin (1:100, Invitrogen) for HFL-1 cells.  Human plasma fibronectin-coated 
plates/dishes (3 μg/cm2, Gibco) were used for EC culture.  Type I collagen pre-coated plates (Iwaki Co. 
Ltd., Japan) were also used for culture of EC derived from iPSC.  Culture of iPSC was performed as 
reported previously50-52, as was feeder-free iPSC culture.  In brief, iPSC were removed from feeder culture 
dishes by incubation with CTK solution® (ReproCell) for 1-2 min at 37oC.  Then the cells were washed 
with phosphate-buffered saline (PBS) and incubated with 0.5× TrypLESelect® (Thermo Fisher Scientific) 
for 4-7 minutes.  After removing TrypLESelect®, the cells were washed with PBS and scraped off the 
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culture dish for sub-culture on dishes coated with laminin-511 E8 (iMatrix-511®, ReproCell).  StemFit® 
(ReproCell) medium was used for feeder-free iPSC culture.  
 
Induction of differentiation  
   Induction of differentiation of iPSC to EC was done by a modification of the previously reported method 
30,31.  Feeder-free iPSC were subcultured in 6-well plates at a density of 0.2×105 cells/well on day -2.  
Differentiation induction medium was prepared with Advanced RPMI 1640® (Thermo Fisher), 2 % B-27 
Minus Insulin® (Gibco), 200 mM L-Glutamine (Gibco), 10 ng/mL of fibroblast growth factor (FGF2, 
ReproCell), 50 ng/mL of VEGF A-165 (Wako Co. Ltd., Japan), and 2 ng/mL of bone morphogenetic protein 
4 (BMP-4, R&D).  The standard culture medium was changed to induction medium with 1% matrigel 
(Corning) on day 0.  Induction medium was exchanged every two days, and differentiation was completed 
on day 5 (Fig.1).  After sorting of EC (iEC) and MC by FACS analysis, only iEC were subjected to 
following subculture.    
 
Cell sorting and flow cytometric analysis 
   Differentiated cells were detached by incubation with ACCUMAX® (Innovative Cell Technologies) for 
15 min at 37 °C. Detached cells were sorted by using a FACS Aria® (BD) with anti-CD309-PE 
(VEGFR-2/KDR, Milteny) and anti-human CD144 (VE-Cadherin)-APC (eBioscience).  Sorted cells were 
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suspended in EC medium and incubated on type I collagen-coated culture plates.  PE mouse IgG1κ 
isotype control (BD) and APC Mouse IgG1κ isotype control (BD) antibodies were used in this experiment. 
For confirmation of ECpa purification efficiency, anti-human CD31 (PECAM-1)-FITC (eBioscience) and 
FITC mouse IgG1 isotype control (BD) were also used.   
 
Immunostaining 
   Culture plates were fixed with 4 % paraformaldehyde for 15 min at room temperature and rinsed with 
PBS.  Cells were permeabilized by addition of chilled methanol for 10 min at -20 °C, followed by washing 
three times with PBS and incubation with 1 % BSA for 1 hour.  After washing three times with PBS again, 
cells were incubated with the primary antibody at the recommended concentration according to the 
manufacturer’s instructions.  Human CD31/platelet endothelial cell adhesion molecule-1 (PECAM-1) 
antibody (R&D), human VE-cadherin antibody (R&D), VEGFR2 antibody (Invitrogen) and human von 
Willebrand Factor (vWF) antibody (Abcam) were used as the primary antibodies.  After incubation, cells 
were washed three times with PBS and then incubated for 1 hour with the secondary antibody (1:50), which 
was goat anti-rabbit IgG-Alexa Fluor 555 (Invitrogen) or goat anti-mouse IgG-Alexa Fluor 488 (Invitrogen).  
Nuclear staining was performed with 4',6-diamidino-2-phenylindole dihydrochloride (DAPI, Invitrogen).  
Since iEC were purified EC by FACS sorting, the expression of vWF protein were done on cytospin samples 
(Auto Smear 120, SAKURA, Tokyo, Japan).     
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Real time quantitative RT-PCR analysis 
The assay of quantification of mRNA levels of iPSC and iPSC-derived endothelial phenotype cells was 
carried out after isolation of total RNA (TRIzol® reagent, Thermo Fisher) using Takara PCR Thermal Cycler 
MP (TP3000) as described previously53.  The sequences of primers used for amplification of vWF and 
GAPDH were follows; vWF forward gaaatgtgtcaggagcgatg, reverse atccaggagctgtccctca, GAPDH forward 
tcaacagcgacacccactcc, reverse tgaggtccaccaccctgttg.      
 
Tube formation assay 
   Before the tube formation assay, 12-well dishes were pre-incubated with 200 μL of extracellular matrix 
for 1 hour at 37 °C.  Then passaged EC (ECpa) from passages 2 to 5 derived from iPSC culture and sorted 
(iEC) were incubated on the matrix for 2 to 6 hrs at 0.5×105 cells/well.  The assay was performed with an 
endothelial Tube Formation Assay® kit (Cell Biolabs).   
 
Co-culture network formation assay 
   This assay was done by a modification of the reported method54.  HFL-1 cells were seeded in 
multi-well plates with F-12K medium at 1.5×105 cell/cm2 and were incubated for 5 days.  Then ECpa were 
seeded onto the HFL-I culture dishes at 1.5×105 cell/cm2 with a VEGF Comp Kit®.  Incubation was 
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continued until 7 days and the EC network assay was performed on day 7.  
 
Purification of lipids 
   Total lipids were extracted from cells by the Bligh-Dyer method as reported previously50, 55.  Briefly, 
cells were washed twice with normal saline, harvested with a scraper, and sonicated before measurement of 
the protein concentration.  Then the protein solution (100 μg) was mixed with methanol and chloroform in 
a glass tube (solution: methanol: chloroform = 900 μL: 2 mL: 1 mL).  The culture medium (10μl) was 
mixed with the methanol and chloroform in a glass tube, and lipids from each medium used for cell culture 
were also extracted as the same manner.  The following internal standards for lipids (1μg) were obtained 
from Avanti Polar Lipids (Alabaster, AL, USA): PC (30:0, 15:0/15:0), PE (34:0, 17:0/17:0), and SM (35:0, 
dihydroxy (d)18:1/17:0).  
 
LC-MS/MS 
   Lipids were analyzed by reverse-phase ultra-high-pressure liquid chromatography (UHPLC) using an 
Acquity UPLC BEH C18 column® (1.7 μm, 2.1 × 50 mm) (Waters, MA, USA) coupled to a 5500 QTRAP® 
mass spectrometer (Sciex Inc., MA, USA), as previously reported50.  A binary gradient was used, which 
consisted of solvent A (acetonitrile:methanol:water (1:1:3) containing 5 mM ammonium acetate) and solvent 
B (2-propanol containing 5 mM ammonium acetate) with the following gradient profile: 0-1 min, 95% A; 
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1-9 min, 5-95% B linear gradient; 9-13 min, 95% B.  The flow rate was 0.3 ml/min and the column 
temperature was 40°C.  The following settings were employed: source voltage 5000 and -4500 V for 
positive and negative, respectively; GS1 50; GS2 80; curtain gas 30; and source temperature 100 °C.  
Multiple reaction monitoring (MRM) of the transitions of individual lipids was done as described 
previously56.  Individual lipid species were normalized against the internal standards, which were PC (30:0, 
15:0/15:0), PE (34:0, 17:0/17:0), and SM (35:0, d18:1/17:0).   
 
Statistical analysis 
   The reported results are data from at least three independent experiments.  Mean values and the 
standard error of the mean (SEM) were calculated.  Student’s t-test was used for assessment of significant 
differences and analyses were performed with 4 step Excel tokei® software (Seiunsya, 2015, Japan). 
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Figure legends  
Figure 1 | Induction of EC from iPSC.  iPSC were transferred from on-feeder culture to feeder-free 
culture.  After passaging on day -2, the cells were stimulated on day 0 with fibroblast growth factor 2 
(FGF2: 10 ng/mL), vascular endothelial growth factor A-165 (VEGF: 50 ng/mL), bone morphogenetic 
protein 4 (BMP4: 2 ng/mL), and Matrigel (1/100 v/v, only on day 0).  The medium was changed every 2 
days and cells were sorted into iEC and MC on day 5.  iEC were cultured for several more passages to 
obtain ECpa, which were used in the network formation assay. 
 
Figure 2 | Assessment of induced EC.  Immunofluorescence staining of iPSC and ECpa (a).  iPSC were 
not positive for PECAM-1, VE-cadherin, KDR and vWF (EC markers), whereas nearly 100% of ECpa were 
positive for PECAM-1, VE-cadherin, KDR and vWF. (BF = bright field) (Scale bar = 100 μm).  Network 
(tube) formation assay (b).  ECpa were cultured in 12-well plates coated with extracellular matrix (ECM).  
i: 0 hours of incubation. ii: 4 hours of incubation. Network formation was observed at 4 hr. (Scale bar=100 
μm).  Co-culture network (tube) formation assay (c). When HFL-1 cells and ECpa were co-cultured, 
networks were formed sterically between HFL-1 cells.   i: Fluorescent immunostaining: PECAM-1 (green), 
DAPI (blue). ii: Magnified view of fluorescent immunostaining.  Arrowhead indicated the tube formation 
by ECpa. (Scale bar = 100 μm). 
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Figure 3 | Changes of phospholipids detected by LC-MS/MS during differentiation of iPSC to ECpa.  
Levels of pPE (a), pPC (b), and SM (c) during differentiation of iPSC to ECpa were examined.  PE (34:0), 
PC (30:0), and SM (35:0) were used as internal standards, with 1μg being added to 100 μg of protein 
solution. (*p<0.05 compared with iPSC) 
 
Figure 4 | Composition of pPE, pPC, and SM in ECpa, HUVEC and HFL-1 cells determined by 
LC-MS/MS.  Levels of pPE, pPC, and SM in ECpa were compared with HUVEC (a-c) and HFL-1 (d-f).  
PE (34:0), PC (30:0), and SM (35:0) were used as internal standards, with 1μg being added to 100 μg of 
protein solution. (*p<0.05) 
 
